NewsArena
Newsarena.ng is an online news media established to disseminate up-to-date and unbiased reportage of issues of public concern, with high level of professionalism, based on truth.

NAFDAC Approves New Vaccine To Fight Malaria

The National Agency for Food and Drug Administration and Control has approved the R21 malaria vaccine manufactured by the Serum Institute of India.

Director General of NAFDAC, Prof Mojisola Adeyeye, disclosed this on Monday at a press briefing in Abuja.

This makes Nigeria the second country to approve the new malaria vaccine developed at the University of Oxford, after Ghana.

Also Read:  Ekiti Decides: Five Guber Candidates Absent At Peace Accord

Prof Adeyeye said the vaccine is indicated for the prevention of clinical malaria in children from 5 months to 36 months of age.

She said the country expects to get at least 100,000 doses of the vaccine in donations soon before the market authorisation will start making other arrangements with the National Primary Health Care Development Agency.

Adeyeye said “NAFDAC in exercising its mandate as stipulated by its enabling law, NAFDAC Act CapN1, LFN 2004 is granting registration approval for R21 Malaria Vaccine (Recombinant, Adjuvanted) manufactured by Serum Institute of India Pvt. Ltd.

Also Read:  Patoranking, DJ Zeal, Ushbebe, Others To Perform At QUILOX Reopening - Shina Peller

“The Marketing Authorization Holder is Fidson Healthcare Ltd in line with the Agency’s Drug and Related Products Registration Regulation 2021.

According to her, the R21 malaria vaccine dossier complied substantially with the best international standards with which the dossier was benched-marked.

She said the Joint Review Committee concluded that the data on the R21 Malaria vaccine were robust and met the criteria for efficacy, safety, and quality.

Also Read:  Ondo 2024: PDP Picks Running Mate For Governorship Candidate


...To get more news updates, Join our WhatsApp Group (Click Here) and Telegram Group(Click Here)
Leave A Reply

Your email address will not be published.